Respira Therapeutics

Respira Therapeutics, Inc. is a drug development company based in Albuquerque, New Mexico, established in 2010. The company specializes in the pulmonary delivery of therapeutics aimed at addressing respiratory diseases with unmet medical needs. Respira focuses on the development and commercialization of passive dry powder inhalers (DPIs) that utilize a novel drug delivery engine and mechanism of action for effective lung therapy. The company has achieved clinical proof-of-principle for its technology, which has demonstrated superior drug dispersion performance compared to existing devices. This positions Respira's DPIs to potentially replace currently marketed inhalation devices and expand inhaled therapies across various drug classes and disease indications, particularly in high-value therapeutic areas. Additionally, Respira maintains a strategic collaboration with United Therapeutics Corporation to further its objectives in this field.